New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDermorphin vs MOTS-c

Dermorphin vs MOTS-c

Side-by-side comparison of key properties, dosing, and research.

Recovery & Repair
Dermorphin
Anti-Aging & Longevity
MOTS-c
Summary
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
Half-Life
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
Estimated 1–2 hours
Admin Route
Subcutaneous (research), Intrathecal (research), Intranasal (research)
SubQ
Research
Typical Dose
Not established for human use; research doses vary widely
5–15 mg
Frequency
Not established
3–5 times per week
Key Benefits
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
  • Improves insulin sensitivity and glucose metabolism
  • Enhances exercise capacity and endurance
  • Reduces age-related metabolic decline
  • Activates AMPK — the master metabolic regulator
  • Promotes fat oxidation
  • Anti-inflammatory effects
  • May extend healthspan via mitochondrial optimization
  • Increases energy and reduces fatigue
Side Effects
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
  • Injection site irritation
  • Fatigue during initial adaptation
  • Unknown long-term profile (limited human data)
Stacks With